Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,580 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06581432RecruitingPhase 2
Zongertinib for advanced cancers with HER2 changes
This trial tests a new pill called zongertinib for people with advanced cancers that have HER2 changes. It may help when other treatments have stopped working, and it targets the HER2 protein to slow or stop tumor growth.
Anchorage, AlaskaAges 18 years+ - NCT07882888RecruitingPhase 2
Immunotherapy drugs with cetuximab for treatable mouth cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus cetuximab for people with oral cancer that can be removed by surgery. The goal is to see if this treatment shrinks tumors and helps patients before their operation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07819760Recruiting
Prostate removal without prior biopsy for suspected cancer
This study looks at whether removing the prostate gland without doing a biopsy first is safe and effective for men with a high PSA and strong signs of cancer on imaging. If you qualify, you would have surgery to remove your prostate, and the tissue would be checked during the operation to guide further treatment.
Moscow, MoscowAges 18 years+ - NCT06101069Recruiting
New MRI technique to identify brain changes after radiation
This study tests a new MRI technique to better tell apart tumor regrowth from tissue changes caused by previous radiation therapy. If you've had brain radiation or have a new brain tumor, this imaging could help guide your next steps.
Cleveland, OhioAges 18–60 - NCT06303193RecruitingPhase 1/Phase 2
Testing a kinase inhibitor drug for MDS and MDS/MPN in adults and teens
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
Bethesda, MarylandAges 12–120 - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Los Angeles, CaliforniaAges 1–25 - NCT06948084RecruitingPhase 2
New drug combo vs usual care for high-risk multiple myeloma
This trial tests whether a new combination of drugs (daratumumab and teclistamab) works better than the usual treatments for multiple myeloma that has come back or stopped responding, especially in people with a high-risk form of the disease. Participants will be randomly assigned to get either the new combo or one of the standard combos.
Coeur d'Alene, IdahoAges 18 years+ - NCT07673887RecruitingPhase 3
Study of a new drug combo for advanced stomach cancer
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
Saint Louis Park, MinnesotaAges 18 years+ - NCT06487481RecruitingPhase 1
Radiation before surgery for recurrent adrenal cancer
This trial tests whether giving radiation before surgery helps people with adrenal cancer that has come back after previous treatment. It aims to see if this approach can improve outcomes for patients who can have surgery at the NIH.
Bethesda, MarylandAges 18–120 - NCT07672483RecruitingPhase 1
Gene therapy for solid tumors that returned after treatment
This trial tests a new type of gene therapy that uses your own immune cells (called myeloid cells) engineered to produce a protein (IL-12) to fight your cancer. It is for people with solid tumors that have not responded to standard treatments.
Bethesda, MarylandAges 18–120 - NCT07332507RecruitingPhase 1
Testing teclistamab for recurrent plasmablastic lymphoma
This trial tests a new drug called teclistamab for people with plasmablastic lymphoma that has come back or not responded to standard treatments. The goal is to see if teclistamab can shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06406465RecruitingPhase 2
Belinostat trial for neuroendocrine cancer based on genetics
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
Bethesda, MarylandAges 18–120 - NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Springdale, ArkansasAges 18 years+ - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
Duarte, CaliforniaAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+ - NCT07572136RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell leukemia
This trial tests a new type of CAR T-cell therapy—a treatment that uses your own immune cells engineered to fight leukemia cells. It is designed for patients with B-cell acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard treatments, and whose leukemia cells have a specific marker called TSLPR.
Bethesda, MarylandAges 18–120 - NCT07879989Recruiting
Tracking breathing changes in adults with Duchenne muscular dystrophy
This study follows adults with Duchenne muscular dystrophy to track how their breathing changes over time. It aims to understand the natural progress of respiratory function, which may help improve future care and treatment planning.
BolognaAges 18 years+ - NCT06885034RecruitingPhase 1/Phase 2
Testing a new drug for advanced bowel or pancreatic cancer
This trial is testing an experimental drug (GSK5764227) either alone or with other treatments for people with advanced colon, rectal, or pancreatic cancer that cannot be removed with surgery. The goal is to see if the drug is safe and effective for these cancers.
Los Alamitos, CaliforniaAges 18 years+ - NCT07326566RecruitingPhase 2
Silevertinib and chemo for a type of glioblastoma
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Birmingham, AlabamaAges 18 years+ - NCT07331428RecruitingPhase 2
Drug combination for recurrent nasopharyngeal cancer
This trial tests a combination of two drugs—an investigational antibody that targets cancer cells (MRG003) and a chemotherapy pill (capecitabine)—along with an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back but hasn't spread. The goal is to see if this approach can help control the cancer.
Fuzhou, FujianAges 18–70 - NCT07644559RecruitingPhase 2
Study of VS-7375 with cetuximab for advanced pancreatic cancer
This trial tests a new drug combination for people with a specific KRAS mutation in pancreatic cancer. It aims to see if the treatment can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06891755Recruiting
Lung deflation procedure for severe emphysema
This study tests a bronchoscopic treatment to release trapped air in severely hyperinflated lungs caused by emphysema. It may help you breathe easier if you have advanced COPD and meet specific lung function and imaging criteria.
Birmingham, AlabamaAges 40–84 - NCT07875582Recruiting
Blood test for better pancreatic cancer diagnosis
This study looks for proteins in the blood that could help doctors tell the difference between pancreatic cancer and non-cancerous pancreatic conditions, such as chronic pancreatitis or benign cysts. By participating, you could help improve early and accurate diagnosis, which may lead to better outcomes for future patients.
IașiAges 18 years+ - NCT07060807RecruitingPhase 3
Patritumab deruxtecan for advanced breast cancer
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
Daphne, AlabamaAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,580 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.